ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025
Rhea-AI Summary
ORIC (Nasdaq: ORIC) will present clinical data for enozertinib (ORIC-114) in previously treated patients with HER2 exon 20 mutant NSCLC at the ESMO Asia Congress 2025 in Singapore (December 5–7, 2025).
The poster (Presentation 981P) is scheduled for Friday, December 5, 2025, 5:15–6:15 p.m. SGT in a poster display session.
ORIC will host a related conference call and live webcast on Saturday, December 6, 2025 at 8:00 p.m. ET; live Q&A will require pre‑registration and the webcast replay will be available via ORIC’s investor website for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ORIC declined 6.14%, reflecting a notable negative market reaction. This price movement removed approximately $76M from the company's valuation, bringing the market cap to $1.16B at that time. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peer biotech names show mixed single-day moves, with several modestly positive (e.g., NUVB, MAZE, ATNF) and one notable decliner (ELVN at -6.1%). No momentum scanner flags or same-day peer headlines suggest this ORIC news is being treated as company-specific rather than part of a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 05 | Clinical data update | Positive | -4.4% | Phase 1b enozertinib EGFR exon 20 data with strong systemic and CNS activity. |
| Dec 05 | Equity inducement grants | Neutral | -4.4% | Inducement stock options and RSUs granted to new non-executive employees. |
| Dec 05 | Clinical data update | Positive | -3.5% | Phase 1b HER2 exon 20 NSCLC enozertinib data with 100% disease control at 80 mg. |
| Dec 04 | Clinical data update | Positive | +3.8% | ESMO data showing robust systemic and CNS activity in EGFR atypical mutations. |
| Dec 03 | Conference presentation notice | Positive | +3.1% | Announcement of late-breaking oral enozertinib presentations and investor call. |
Recent ORIC news around enozertinib has often been clinically positive, yet share reactions were mixed, with several data-heavy ESMO updates followed by negative one-day moves and only some announcements seeing aligned positive price action.
Over early December 2025, ORIC has been centered on enozertinib at the ESMO Asia Congress 2025. The company announced late-breaking oral presentations and then reported Phase 1b data in EGFR atypical and EGFR exon 20 NSCLC, plus separate HER2 exon 20 data, generally showing meaningful response rates and CNS activity. Despite these updates, the stock saw both positive and negative single-day moves. Alongside this, ORIC disclosed inducement equity grants and previously provided financial and pipeline updates, framing today’s poster notice as part of a broader, ongoing data roll-out rather than a standalone inflection.
Market Pulse Summary
The stock moved -6.1% in the session following this news. A negative reaction despite this largely logistical poster announcement would fit recent patterns where clinically positive ESMO updates sometimes coincided with weak price days. The news reiterates ORIC’s enozertinib program rather than introducing new topline efficacy data, so profit-taking or broader risk sentiment could dominate. Prior insider sales and financing activity may add to caution, making downside moves more sensitive even around neutral, scheduling-type communications.
Key Terms
phase 1b medical
her2 exon 20 medical
nsclc medical
her2 inhibitor medical
webcast technical
AI-generated analysis. Not financial advice.
Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced a poster presentation highlighting data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025 taking place December 5-7, 2025 in Singapore. The poster will focus on data in previously treated patients with HER2 exon 20 mutant NSCLC.
| Poster presentation details: | |
| Title: | Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant |
| EGFR and HER2 Inhibitor, in Patients with HER2 Exon 20 | |
| Mutant NSCLC: Randomized Dose Optimization | |
| Presentation Number: | 981P |
| Session Type and Title: | Poster Display session and cocktail |
| Session Date & Time: | Friday, December 5, 2025; 5:15 – 6:15 p.m. SGT |
Full abstracts are available for public viewing via the ESMO Asia Congress website.
Conference Call and Webcast Details
In conjunction with the ESMO Asia Congress, ORIC will host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. A live webcast and audio archive of the conference call will be available through the investor section of ORIC’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib (ORIC-114), a brain-penetrant inhibitor that selectively targets EGFR exon 20, EGFR atypical, and HER2 exon 20 mutations, being developed across multiple genetically defined cancers. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
FAQ
What data will ORIC (ORIC) present for enozertinib at ESMO Asia 2025?
When and where is the ORIC poster for enozertinib presented at ESMO Asia 2025?
How can investors join ORIC’s conference call and webcast for the ESMO Asia presentation?
When is ORIC’s conference call/webcast for the ESMO Asia poster and is there a replay?
What is the session type and presentation number for ORIC’s enozertinib poster at ESMO Asia 2025?
